NMDAR antagonism alters mesolimbic, hippocampal, and cortical function, acutely reproducing the positive, cognitive, and negative symptoms of schizophrenia. These physiological and behavioral effects may depend differentially on NMDAR subtypeand region-specific effects. The dramatic electrophysiological signatures of NMDAR blockade in rodents include potentiated high frequency oscillations (HFOs, ∼140 Hz), likely generated in mesolimbic structures, and increased HFO phase-amplitude coupling (PAC), a phenomenon related to goal-directed behavior and dopaminergic tone. This study examined the impact of subtype-specific NMDAR antagonism on HFOs and PAC. We found that positive-symptom-associated NR2A-preferring antagonism (NVP-AAM077), but not NR2B-specific antagonism (Ro25-6985) or saline control, replicated increases in HFO power seen with nonspecific antagonism (MK-801). However, PAC following NR2A-preferring antagonism was distinct from all other conditions. While θ -HFO PAC was prominent or potentiated in other conditions, NVP-AAM077 increased δ -HFO PAC and decreased θ -HFO PAC. Furthermore, active wake epochs exhibiting narrowband frontal δ oscillations, and not broadband sleep-associated δ , selectively exhibited δ -HFO coupling, while paradoxical sleep epochs having a high CA1 θ to frontal δ ratio selectively exhibited θ -HFO coupling. Our results suggest: (1) NR2A-preferring antagonism induces oscillopathies reflecting frontal hyperfunction and hippocampal hypofunction; and (2) HFO PAC indexes cortical vs. hippocampal control of mesolimbic circuits. θ (∼6-11 Hz) and δ (∼1-4 Hz) bands. Notably, the mesolimbic θ and δ oscillations that modulate HFO amplitude are driven by rhythmic activity generated in hippocampus 20, 21 and prefrontal cortex (PFC) 22-24 , respectively 15, 17 . Evidence indicates that inputs from PFC and hippocampus compete for control over mesolimbic circuits [25] [26] [27] [28] [29] [30] [31] [32] [33] . If HFOs predominantly reflect mesolimbic population activity [15] [16] [17] [18] [19] , their phase modulation may reflect the strength of frequency-specific inputs to mesolimbic circuits, either from cortex at δ frequencies or from hippocampus at θ frequencies.
Introduction
NMDA hypofunction is one of the leading hypotheses of schizophrenic pathophysiology 1, 2 , mainly due to the ability of NMDA receptor (NMDAR) antagonists such as ketamine and phencyclidine to acutely reproduce the positive, cognitive, and negative symptoms of schizophrenia. NMDARs play a variety of roles in different brain structures, making it challenging to understand how NMDA hypofunction impacts different cells, circuits, and systems to bring about its multiple behavioral effects. Indeed, the recent genetic delineation of multiple schizophrenia subtypes 3 suggests that NMDA hypofunction -in its replication of multiple symptom types -may actually model several "schizophrenias" simultaneously. Critical details are missing, however. For example, while several experiments have examined the effects of ketamine on fast and slow oscillations and their phase coupling [4] [5] [6] [7] , it remains unknown how these changes depend on ketamine's multiple pharmacological actions, including actions on NMDARs, D2 dopamine (DA) receptors, and HCN1 channels [8] [9] [10] .
A natural way to link molecular changes, such as NMDA hypofunction, to behavioral outcomes, such as schizophrenic symptoms, is to study mesoscale phenomena -signatures of coordinated population activity such as brain rhythms in the electroencephalogram (EEG) and local field potentials (LFP) 11 . Both schizophrenia and NMDAR antagonist drugs induce an array of changes in brain rhythms and their coordination [11] [12] [13] . Recently, the study of brain rhythms has provided support for the hypothesis that the multiplicity of effects of NMDAR antagonism results in part from the heterogeneity of NMDAR subtypes. Antagonism of the NR2A receptor subtype, but not antagonism of NR2B, C or D receptor subtypes, has been shown to replicate the changes in γ power seen with positive symptoms in schizophrenia and with non-specific NMDAR antagonists 14 . Thus, NR2A receptor hypofunction may play a key role in mediating schizophrenia's positive symptoms.
One of the most marked and robust oscillatory changes observed with acute NMDAR antagonism in rodents is the potentiation of so-called high-frequency oscillations (HFOs, ∼120-160 Hz) [4] [5] [6] [7] . These narrowband, highly coherent rhythms are carried by mesolimbic circuits, modulating neuronal firing in the VTA 15 and amygdala 16, 17 as well as current sources and sinks in the nucleus accumbens (NAcc) 18, 19 . HFO amplitude is often modulated by the phase of low-frequency rhythms in the 1 Methods
Recordings
All experiments were performed in accordance with National Institute of Health guidelines and were approved by the Institutional Animal Care and Use Committee of Beth Israel Deaconess Medical Center. Six (n = 6) rats were housed in a temperature and humidity-controlled room with 12h/12h light/dark cycle; food and water was available ad libitum both in the home cage and during recordings. Stainless steel screws were used to record EEG over the frontal (1 mm anterior and 2 mm lateral to bregma) and occipital (6.5 mm posterior and 3 mm lateral to the bregma) cortices, and pairs of twisted wires were implanted in the hippocampus (CA1, as identified by the phase of θ relative to occipital cortex) to record LFPs. Two additional screw electrodes were inserted ∼5 mm anterior to bregma and over the cerebellum for ground and reference, and electromyograms (EMG) were recorded using multithreaded wires in the neck muscles. Recordings began after a 7-to 10-day recovery period following chronic implantantion, and experiments with drug injections started after several days of control recordings. Each rat was injected (in 1 mL/kg volume, subcutaneously, on different days and with at least 3 days in between) with nonselective NMDAR antagonist MK-801 (0.2 mg/kg, Tocris), NR2A-preferring antagonist NVP-AAM077 (20 mg/kg, Novartis), NR2B-selective antagonist Ro25-6985 (10 mg s/c, Tocris), and saline vehicle as a control. Recordings started in the early morning, beginning ≥ 3 h prior to injection and ending ≥ 16 h after injection. Data were divided into ∼16 s epochs for further analysis.
Spectral Analyses
Power spectra were calculated for each epoch using the Thompson multitaper method. Power at each frequency was expressed as a percentage of mean baseline power, defined to be the mean power (at a given frequency) over the 4 h preceding injection. Power within the δ (1-5 Hz), θ (5-11 Hz), high γ (40-90 Hz), and HFO (120-160 Hz) bands was calculated by summing spectral power over the frequencies within these bands.
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Vigilance States
EMG power and CA1 θ power were used to automatically categorize each epoch into one of three behavioral states: active waking (AW), characterized by high θ and high EMG power; paradoxical sleep (REM), characterized by high θ power and low EMG power; and quiet waking/non-REM sleep (QW/nREM), characterized by low θ and low EMG power. Candidate REM epochs were further checked by manual scoring.
PAC Analyses
PAC comodulograms were computed for all epochs. First, oscillations were extracted from each epoch via convolution with 7-cycle complex Morlet wavelets, having central frequencies spaced every 0.25 Hz from 1 to 12 Hz and every 5 Hz from 20 to 200 Hz. Instantaneous amplitude and phase time series A f (t) and φ f (t) were calculated for each frequency f as the absolute value and angle of the resulting complex time series. For each pair of high-frequency Hz) amplitude and low-frequency (1-12 Hz) phase time series, an inverse entropy index 35 was computed. The resulting inverse entropy measure (IE) quantifies the degree of phase-amplitude dependence. An IE of zero indicates no phase-amplitude dependence (a uniform distribution of amplitude with respect to phase). An IE of one is obtained when all the amplitude occurs in a single phase bin. In general, higher IE is awarded to distributions exhibiting a stronger dependence of amplitude on phase, including distributions exhibiting multiple peaks.
For a finite data series, IE will always take finite nonzero values, even when no coupling is present in the data. To remove these non-coupling related influences, we used surrogate data to estimate "background" values of IE. These background IE values were estimated using epoch-shuffled surrogate data: for each h relative to injection in each subject, and for each frequency pair, 1000 random pairings of non-simultaneous high-frequency amplitude and low-frequency phase time series were used to calculate a distribution of surrogate IE values. For each pair of frequencies, this distribution was used to z-score the observed IE, yielding a z-score of coupling significance or modulation index (MI) for that epoch and pair of frequencies.
Isolating Epochs of Narrowband δ
To determine epochs containing narrowband δ , we calculated the entropy of the spectral power in the δ band. The spectrum obtained using the Thompson multitaper method was smoothed by convolution with a Gaussian of standard deviation 0.075 Hz. The smoothed spectrum within the δ range (0.5 -4.5 Hz) was normalized to have unit sum. The entropy of this distribution of δ power by frequency was computed, resulting in a measure of the uniformity of the distribution of spectral power across frequencies (δ entropy). The higher the δ entropy value, the more uniformly power is distributed across the δ band; the lower the δ entropy value, the "peakier" is the distribution of spectral power in the δ band.
Next, we calculated the values of δ entropy corresponding to the first and last percentile of observed δ entropy across all recorded waking epochs, for each drug. Epochs having a δ entropy less than or equal to the first percentile were considered to exhibit narrowband δ , while epochs having a δ entropy greater than or equal to the last percentile were considered to exhibit broadband δ . Median PAC comodulograms were plotted for these two subsets of epochs.
Correlating Spectral Power and PAC
To correlate spectral power and PAC, values of MI for all frequency pairs, and values of power in the θ and δ bands, were correlated during the first 4 h following injection in all conditions.
Isolating Epochs with High θ /δ Ratio
To determine epochs containing high θ /δ ratio, we took the ratio of the band power within the θ and δ bands. Within each vigilance state, the epochs having θ /δ ratio within the first and last percentile of observed θ /δ ratios was selected, by the same procedure as for δ entropy, above. Median PAC comodulograms were plotted for these low and high θ /δ ratio epochs.
Statistics
As IE and spectral power take positive values, they are not normally distributed (even after z-scoring against surrogate distributions). This was confirmed using Kolmogorov-Smirnov tests. Thus, median values are used in visualizations, and ranksum tests were used for comparisons to saline. To quantify the similarities and differences in IE and power between drugs pre-and post-injection, we calculated pairwise ranksum tests (comparing each drug to saline injection) for each six min period relative to injection. These tests compared the n = 6 observations from each rat (averaged over the six min period) for drug and saline. Tests were performed on sums of MI over frequency ranges of interest and on baseline-normalized band power. 
Results
MK-801 and NVP-AAM077 Have Similar Effects on High Frequency Rhythms
Both MK-801 and NVP-AAM077 administration were observed to result in prolonged periods (∼4-6 hs) of wakefulness, as opposed to Ro25-6985 and saline. The animals mostly exhibited abnormal "stereotyped" behaviors, such as head-banging, prolonged climbing-like movements in the corner of the cage, etc. 14, 34 During these four hs, high γ and HFO power increased dramatically in these two conditions ( Fig. 1) , roughly following the time course of the abnormal low γ increases reported following these drugs 14, 36, 37 . In contrast, Ro25-6985 did not induce persistent changes in fast oscillations 34 . MK-801 and NVP-AAM077 (but not Ro25-6985) also affected slow oscillations. Previous studies 6, 37 reported layer dependent changes in hippocampal θ power after MK-801 administration, with θ decreases in superficial layers of CA1 accompanying strong θ increases in deep electrodes placed at or below the hippocampal fissure. In our current sample, θ showed little change following MK-801 administration, but was strongly suppressed (relative to saline) after NVP-AAM077 administration. This suppression lasted for 4 h in occipital cortex and CA1, and for 2 h in frontal cortical recordings. Following
4/16
NVP-AAM077, power in the δ band showed a biphasic reaction: it was suppressed in the first h, and then started to rise and reached significantly elevated levels in the frontal cortex during the 3 rd to 6 th h post-injection ( Fig. 1 , right middle column). In contrast, δ did not increase following MK-801until 4 h after injection, when changes in HFO and high γ (and PAC) had worn off. , and S1; here they are shown with individually optimized color scales, to more clearly show the pattern of PAC in each region during the h of largest effect for each drug. The right two columns show timeseries of summed PAC over the θ -HFO (red rectangle and time series) and δ -HFO (green rectangle and time series) frequency ranges from 2 h pre-injection to 6 h post-injection. Thick lines are drug time series; thin lines are saline time series; stars indicate 6 min periods for which drug PAC is significantly higher (above) or lower (below) than saline (ranksum test, significance level = 0.05).
MK-801 and NVP-AAM077 Induce Primarily θ -HFO and δ -HFO PAC, Respectively
Following saline injection (Figs. 2, S1), we observed region-specific profiles of PAC. In frontal cortex, the most prominent coupling was between δ phase and high γ power, with weaker coupling between θ and high γ/HFOs. In occipital cortex and CA1, prominent θ -HFO PAC was observed. In CA1, weak θ -γ PAC was also visible.
In agreement with previous reports for ketamine [5] [6] [7] , median PAC comodulograms following MK-801 injection revealed dramatic increases in θ -HFO PAC in all brain regions relative to saline injection (Figs. 2, 3), suggesting that ketamine increases PAC 5-7 through its action at NMDARs, and that its D2 receptor agonism is not necessary for increased coupling. PAC increases were most dramatic in frontal cortex, followed by occipital cortex, and then by CA1. These increases in θ -HFO PAC were accompanied by statistically significant but less dramatic increases in δ -HFO PAC. In CA1, MK-801 injection also led to an increase in θ -γ PAC (Figs. 2, 3).
Following NVP-AAM077 injection, the largest observed effect was an increase in δ -HFO PAC at all sites, relative to saline (Figs. 2, 4) . In contrast, only minor increases in θ -HFO PAC were seen in frontal cortex, and decreases in θ -HFO PAC were observed in occipital cortex and CA1, relative to saline (Fig. 2, rightmost column, Fig. 4 ). No changes in θ -γ or δ -γ PAC were observed. This divergence is especially noteworthy, given that NVP-AAM077 is only NR2A-preferring (not strongly NR2A-selective). Following injection of Ro25-6985, few prolonged changes in PAC were observed (not shown). θ coupling of γ and HFO power is known to be higher during θ states such as AW and REM. As vigilance states are usually defined by EMG activity and EEG θ power (see Section 1.3), behavioral analyses of our data using traditional terms and scoring may be confounded by the decreases in EEG θ power observed following NVP-AAM077 injection. Rats were awake 4-6 h after both MK-801 and NVP-AAM077 injections 14, 34 . Following MK-801, even though the animals were not engaged in normal θ -associated exploratory behavior, increased EMG activity was mostly accompanied by θ , and an increase in traditionally scored active wake (AW) epochs relative to saline was observed ( Fig. S2 ). On the other hand, there were fewer θ states following NVP-AAM077 injection, so observed increases in wakefulness following NVP-AAM077 were not reflected in a change in the proportion of AW epochs (Fig. S2 ), but could be reflected in an increase in traditionally scored quiet wake (QW) epochs and a simultaneous decrease in traditionally scored non-REM sleep (nREM) epochs relative to saline. Thus, to address the relationship between changes in vigilance states and changes in HFO PAC, in addition to behavioral analyses using the traditional vigilance state categories ( Fig. S2 , see Section 1.3), we also restricted our analyses to only AW epochs ( Fig. S3 ), or only QW/nREM epochs (Fig. S4 ), and found that the distinct patterns of PAC described above persisted. Thus, MK-801 induced increased θ -HFO coupling, relative to saline, within both AW and QW/nREM epochs; and NVP-AAM077 induced increased δ -HFO coupling and decreased θ -HFO coupling, relative to saline, within both AW and QW/nREM epochs. Evidence suggests that NMDAR antagonist-potentiated HFOs have current generators in mesolimbic circuits, and are then volume conducted to other brain regions [15] [16] [17] [18] [19] . However, spontaneous HFOs may be generated locally in other brain regions, including hippocampus 18 . We observed small differences in the time course and spectral parameters of HFO power between recording sites, and differences between sites in HFO PAC, indicating that the predominance of δ and θ oscillations in frontal cortex and CA1, respectively, might bias the detection of δ -HFO PAC in frontal cortex and the detection of θ -HFO PAC in CA1. Thus, for further analyses of the precise timecourse and dynamics of HFO phase modulation, and its correlation with δ and θ power, we utilized only measurements of PAC taken from the "neutral" occipital cortex.
Following NVP-AAM077 Injection, δ -and θ -HFO Phase Coupling are Dissociable in Time
To explore the relationship between θ -HFO and δ -HFO PAC appearing in occipital cortex following NVP-AAM077 injection on a short time scale, we examined individual epochs and 6 min segments of EEG. While both θ -HFO and δ -HFO PAC were observed in occipital cortex during the h of greatest effect following NVP-AAM077 injection (Fig. 5, top left) , the top quartiles of epochs for θ -HFO and δ -HFO PAC during this h (Fig. 5 , top middle and right) revealed a dissociation between these two phenomena. In individual animals, the time-courses of δ -HFO and θ -HFO PAC at 6 min resolution were not aligned (Fig. 5 , bottom left), and in the 4 h following injection, the correlation between δ -HFO PAC and θ -HFO PAC across animals was not significant (p = 1), with the two variables showing a slightly negative relationship (Fig. 5, bottom right) .
In contrast, in the h of greatest effect following MK-801 injection, while the top quartile of epochs for θ -HFO PAC exhibited HFO coupling only to θ frequencies, the top quartile of epochs for δ -HFO PAC exhibited both δ -and θ -HFO PAC, and δ -and θ -HFO PAC were significantly correlated (p = 9.17x10 −5 ) in the 4 h post-injection (Fig. S5 ). This suggests that the elevation in 
δ -HFO PAC is Restricted to Epochs Containing Narrowband δ
Since δ power may increase during both sleep and wake, but only wake was seen in the 4 h following NVP-AAM077 injection, we hypothesized that the expression of δ -HFO PAC in physiological conditions might depend on the presence of wake-associated narrowband δ oscillations 23, 24 . This waking δ rhythm is different from the broadband δ of inactivity and slow-wave sleep 23, 24 , and may be cognitively important 38 . Thus, we sought to hone in on δ -HFO coupling by selecting only those active waking epochs (across all four drugs) in which narrowband δ was observed in frontal electrodes.
To establish that δ oscillations were narrowband, we calculated the entropy of the spectrum within the δ band (treating it as a probability distribution) for the frontal EEG for each epoch (see Methods). The resulting measure of δ entropy quantified the uniformity of spectral power across the δ band. Thus, high δ entropy epochs exhibited broadband δ , while low δ entropy epochs exhibited "peakier", narrowband δ . Over all waking epochs for each drug, we determined the δ entropy values marking the first and last percentiles of observed δ entropy values, and used these to define narrowband and broadband δ epochs, respectively. Figure 6 compares median comodulograms from occipital electrodes for narrowband and broadband δ epochs, for each drug. It shows that δ -HFO PAC is exclusively associated with narrowband δ epochs, and nearly invisible in broadband δ epochs, across conditions.
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Narrowband Delta Active Wake . Narrowband frontal δ differentiates AW epochs exhibiting δ -HFO coupling. Median (n=6) comodulograms for the AW epochs for which the frontal LFP has a narrowband peak in the δ band and exhibit δ -HFO coupling (left), and for the AW epochs exhibiting broadband frontal δ and an absence of δ -HFO coupling (right).
θ -HFO and δ -HFO PAC are Correlated with CA1 θ and Frontal δ , Respectively
Over the same period that HFO phase-coupling switched from θ to δ frequencies, spectral analysis revealed a switch in the relative dominance of θ and δ power in the areas where these slow oscillations most prominently occur and are most likely generated, i.e., in hippocampal CA1 and frontal cortex, respectively 20, 21, 23, 24 (Fig. 7) . In contrast, no switch was seen in the relative dominance of CA1 δ and frontal θ (not shown). Comparison of baseline-normalized spectral power in the θ and δ bands between h 1 and h 4 post-injection revealed that while frontal δ increased and CA1 θ decreased highly significantly (p = 0.0198 and p = 1.173x10 −5 , respectively), frontal θ and CA1 δ did not change (p = 0.815 and p = 0.931, respectively). These observations held even when we restricted our analysis to AW epochs ( Fig. S6 ; frontal δ increase, p = 3.4475x10 −5 ; CA1 θ decrease, p = 2.1254x10 −4 ; frontal θ , p = 0.1855; CA1 δ , p = 0.1540).
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Hour 1 Postinj. We hypothesized that these synchronous changes in PAC and spectral power were related. To further establish the connection between CA1 θ and θ -HFO PAC on one hand, and between frontal δ and δ -HFO PAC on the other, we correlated the values of PAC calculated at all frequency pairs with spectral power summed over the δ and θ bands in frontal cortex and CA1, respectively (Fig. S7 ), at the ∼16 second timescale of epochs. This analysis was repeated for all injections, including saline and different NMDAR blockers, and revealed a universal relationship between slow oscillations and HFO modulation. The results show in particular that δ -HFO and δ -high γ PAC were positively correlated, whereas occipital and CA1 θ -HFO PAC were negatively correlated, with frontal δ power (left panels, Fig. S7 ). In contrast, occipital and CA1 θ -HFO PAC were positively correlated with CA1 θ power, and δ -HFO PAC was negatively correlated with changes in spectral power in the θ band in CA1 (right panels, Fig. S7 ). These observations held for AW epochs alone (Fig. S8 ). This is especially noteworthy given that θ and δ power were either slightly positively correlated (following MK-801, ρ = 0.194 and p = 2.19x10 −5 ; following NVP-AAM077, ρ = 0.217 and p = 2.06x10 −6 ; following Ro25-6985, ρ = 0.111 and p = 0.0152) or uncorrelated (following saline, p = 0.127) in the 4 h post-injection.
θ -HFO PAC is Highest During REM Epochs Having High θ /δ Ratio
To further probe the dependence of θ -HFO PAC on hippocampal θ , we sought epochs exhibiting high CA1 θ and low frontal δ power. This oscillatory profile is exhibited during REM, and it has been shown previously that θ -HFO PAC is elevated during REM relative to both wake and non-REM sleep 39 . We examined the relationship of NMDAR antagonist potentiated θ -HFO PAC to CA1 θ oscillations using the θ state of REM, and the ratio of CA1 θ power to frontal δ power. Over all REM epochs for all drugs, we determined the values of the θ /δ ratio marking the first and last percentiles of observed θ /δ ratios, and used these to define low and high θ /δ ratio epochs, respectively. Figure 8 shows that θ -HFO PAC is exclusively associated with high θ /δ ratio REM epochs, and nearly invisible in low θ /δ ratio REM epochs, across conditions. 
Discussion
The major findings of this study are that nonspecific NMDAR blockade primarily increased θ -HFO coupling shortly after systemic administration of MK-801, whereas the NMDAR subunit-specific NR2A-preferring antagonist NVP-AAM077 induced a delayed increase in δ -HFO coupling lasting for h and accompanied by a decrease in θ -HFO coupling. These coupling changes did not depend on changes in vigilance state following drug injection. Our observations agree with results on the administration of the non-specific NMDAR antagonist ketamine [4] [5] [6] [7] 37 . We show for the first time that changes in HFO phase-coupling following ketamine administration are most likely due to its action on NMDAR and independent of its action at D2 dopamine receptors and HCN1 channels.
Our results allow the formulation of new hypotheses regarding the control and function of mesolimbic circuits. Our observations suggest that subunit-specific changes reflect an association between the dominant frequency of HFO PAC and the power of frontal δ and hippocampal θ oscillations. Following NVP-AAM077 injection, the remarkable predominance of δ -HFO PAC was correlated with frontal δ power, and across drugs, the presence of narrowband frontal δ oscillations characteristic of waking 23, 24 could be used to distinguish epochs exhibiting δ -HFO PAC. On the other hand, θ -HFO PAC was correlated with CA1 θ power, increased during waking locomotion in all conditions, and was observed only during REM epochs exhibiting an elevated ratio of CA1 θ power to frontal δ power.
We hypothesize that the abnormal increases in δ -HFO PAC and HFO power observed following NVP-AAM077 administration are signatures of prefrontal disinhibition, induced via blockade of NMDARs of NR2A subtype preferentially expressed by PV+ interneurons. However, the blockade of NMDARs in nucleus reuniens of the thalamus, an important node mediating interactions between PFC and hippocampus 24, 62 , also leads to altered prefrontal-hippocampal balance as well as to overexpression of δ rhythms in thalamus and limbic structures [63] [64] [65] [66] [67] . Additionally, the relationship between the narrowband δ described here and previously 24 and the respiratory rhythm [47] [48] [49] [50] [51] 68 is an important question for further investigation.
It is tempting to hypothesize that the distinct HFO coupling profile observed following NR2A-preferring blockade may contribute to the pathological information processing seen with NVP-AAM077 and MK-801, but not Ro25, administration, through dysfunction of executive control mechanisms. Indeed, our results suggest that the increase in δ -HFO PAC observed following MK-801 injection is not merely a "spectral leakage" artifact of increased θ -HFO PAC, but rather that both θ -HFO and δ -HFO coupling are potentiated by nonspecific NMDAR antagonism, although the expression of increased δ -HFO PAC seems to depend on the concurrent presence of potentiated θ -HFO PAC. Interactions between hippocampal and prefrontal NAcc afferents are abnormal in a developmental model of schizophrenia 52, 58 , and an increase in both hippocampo-and cortico-mesolimbic drives, resulting in "focused attention on multiple contingencies", may play a role in the "disrupted focus and ... overwhelming bombardment of stimuli" of schizophrenia 52 . Increased PFC drive to motivational circuits is also hypothesized to be a causal factor in depression 69 , and blockade of NR2A-subtype NMDARs may contribute to the acute induction of negative symptoms with NMDAR antagonism. Further exploration of the behavioral effects of subtype-specific NMDAR antagonism, and their relationship to the altered patterns of rhythmic activity reported here, will be crucial to testing these hypotheses. Figure S1 . Region-specific PAC patterns following saline injection. Median (n=6) comodulograms for the 1 h preceding and the 4 h following saline injection, shown for frontal (top), occipital (middle), and CA1 (bottom) electrodes (simultaneous recordings). Overlaid white traces show the mean spectral power at frequencies below 12 Hz for each h.
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